A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).

Yang Zhang,Miao Zhen Qiu,Jufeng Wang,Yanqiao Zhang,Xianglin Yuan,Tao Zhang,Jinchun Yan,Gaozhun Xiong,Yanping Ji,Xuejun Liang,Gang Xia,Rui Hua Xu

A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).

2021

Yang Zhang
Miao Zhen Qiu
Jufeng Wang
Yanqiao Zhang
Xianglin Yuan
Tao Zhang
Jinchun Yan
Gaozhun Xiong
Yanping Ji
Xuejun Liang
Gang Xia
Rui Hua Xu

e16059Background: ARX788 is a novel antibody drug conjugate (ADC) that consists of human epidermal growth factor receptor 2 (HER2) targeted monoclonal antibody (mAb) linked to a cytotoxic payload, ...

Keywords:

Medicine
Cytotoxic T cell
in patient
Gastroesophageal Junction Adenocarcinoma
Antibody-drug conjugate
Cancer research
Human Epidermal Growth Factor Receptor 2
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations